A 63-year-old man with arterial hypertension was admitted to the Department of Cardiac Surgery due to ascending aortic aneurysm with concomitant severe aortic regurgitation. Aortic valve sparing surgery with the reimplantation of the coronary arteries12 was performed using a prosthetic gelatin-sealed polyester vascular graft (Gelweave; Vascutek Terumo). Six days after the initial surgery, biological aortic valve replacement was necessary because of residual regurgitation of the aortic valve.
After the second procedure, the initial postoperative course was favorable. On post-op day (POD) 13 after the first surgery, his inflammatory markers were elevated (C-reactive protein [CRP] 107 mg/L, leukocytosis 15x109/L), and at that time without any clinical signs of infection. Echocardiography showed small pericardial effusion without other signs of graft or valve malfunction. The patient deteriorated the next day (POD 14), with signs of sepsis and spiking fever. Further increase in his inflammatory markers (CRP 202 mg/L, procalcitonin remained low 0.17 pg/mL) was observed. A computed tomography (CT) scan revealed periaortic fluid and a small pericardial effusion. (Figures 1, Figure 2, and Figure 3). There was no air or signs of an abscess. After obtaining blood cultures, empiric broad-spectrum antimicrobial therapy with imipenem/cilastatin and vancomycin was initiated, and the patient was admitted to the intensive care unit.
On POD 16, echocardiography showed significant pericardial effusion, while valve and graft function remained normal. A surgical reexploration was performed with no signs of intrathoracic infection detected. Samples of pericardial effusion and intrathoracic tissue were collected for microbiological analysis.
Despite the broad-spectrum antimicrobial therapy, the patient remained septic (CRP values remained above 250 mg/L), although the surgical wound showed no signs of infection. Four days later (POD 20), there was sternum instability; the patient underwent a reoperation. Intraoperatively, pus was evident in the pericardium. No signs of graft dehiscence were observed, although necrotic tissue was present around the graft. Sternal wires were removed, radical debridement of the perigraft region and thoracic cavity with lavage was performed, and NPWT with instillation (V.A.C. ULTA; 3M + KCI) was administered. Antiseptic fluid (0.02% polihexanide; Prontosan; B. Braun Medical AG) was instilled over the infected region for 10 minutes, after which continuous negative pressure (-125 mm Hg) was applied for 60 minutes. The same antibiotic therapy continued, because Gram stains of pericardial fluid were negative, and no growth was observed on standard microbiological cultures of pericardial effusion. Blood cultures remained sterile in the first 10 days of incubation. On POD 23, blood cultures were positive, and a microbiologist observed a growth of small colonies of bacteria without cell walls on blood cultures as well as in all the intraoperative tissue samples. Mycoplasma hominis was identified using real-time polymerase chain reaction.13
Based on the identified microorganism, the antibiotic therapy was changed to tigecycline 50 mg twice daily and levofloxacin 500 mg BID intravenously. Initially, the authors did not opt for doxycycline due to unpredicted gut absorption of oral therapy in the critically ill patient.14 After consultation with a clinical pharmacologist, the authors decided to install tigecycline in the thoracic cavity using NPWT with instillation and dwell time (NPWTi-d; V.A.C. VERAFLO Therapy; 3M + KCI). The standard reticulated open cell foam dressing (V.A.C. VERAFLO CLEANSE CHOICE Dressing; KCI + 3M) was used. The authors irrigated the thoracic cavity twice daily with a solution of 50 mg of tigecycline in a 5% glucose solution. After instillation, the solutions were allowed to dwell for 15 minutes, followed by 3 hours of -125 mm Hg continuous negative pressure. Dressing changes were performed every 2 days. No side effects of this therapy were observed, although the authors were aware of the potentially large reabsorption capacity of the thoracic cavity. Four additional surgical debridements were required during the next 10 days, but inflammatory markers began to decrease, and the patient became afebrile and stable shortly after the change of therapy.
The authors used NWPTi-d for 8 days. The patient was switched to oral monotherapy with doxycycline 100 mg twice daily after 23 days of parenteral therapy. The patient was discharged from the hospital after 12 weeks of therapy and continued therapy with doxycycline 100 mg BID for another 9 months. At the 12-month follow-up visit, he had no clinical problems, computed tomographic angiography of the thorax showed no signs of perigraft inflammation, and inflammatory markers were low; the authors decided to discontinue the antibiotic treatment. Two years later, the patient is clinically stable, with no recurrent episodes of infection and an improved quality of life. The patient continues to be managed on an outpatient basis.